In a post hoc analysis of two clinical trials, Maassen et al. demonstrated that 40% of patients with early RA or undifferentiated arthritis experienced disease flare after primary glucocorticoid discontinuation despite background treatment with conventional synthetic DMARDs.
![](https://www.the-rheumatologist.org/wp-content/uploads/2022/10/shutterstock_1680809983-150x150.jpg)